These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36096976)

  • 41. [PATHOGENESIS AND FUTURE TREATMENT OF SEVERE OCULAR ALLERGIC DISEASES].
    Fukuda K
    Arerugi; 2021; 70(3):171-177. PubMed ID: 34011771
    [No Abstract]   [Full Text] [Related]  

  • 42. A Randomized, Controlled Trial of Cyclosporine A Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: The VEKTIS Study.
    Leonardi A; Doan S; Amrane M; Ismail D; Montero J; Németh J; Aragona P; Bremond-Gignac D;
    Ophthalmology; 2019 May; 126(5):671-681. PubMed ID: 30593775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops].
    Ebihara N
    Arerugi; 2010 Nov; 59(11):1525-31. PubMed ID: 21119297
    [No Abstract]   [Full Text] [Related]  

  • 44. Predominance of infiltrating IL-4-producing T cells in conjunctiva of patients with allergic conjunctival disease.
    Matsuura N; Uchio E; Nakazawa M; Yago T; Matsumoto S; Ohno S; Minami M
    Curr Eye Res; 2004; 29(4-5):235-43. PubMed ID: 15590468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cyclosporine A 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis.
    Ghiglioni DG; Bruschi G; Centonze S; Calcinai E; Cozzi L; Osnaghi S; Viola F; Marchisio PG
    J Pediatr Ophthalmol Strabismus; 2022; 59(4):279. PubMed ID: 35856429
    [No Abstract]   [Full Text] [Related]  

  • 46. Tear cytokines in acute and chronic ocular allergic inflammation.
    Cook EB
    Curr Opin Allergy Clin Immunol; 2004 Oct; 4(5):441-5. PubMed ID: 15349046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions.
    Fukushima A; Yamaguchi T; Ishida W; Fukata K; Liu FT; Ueno H
    Clin Exp Ophthalmol; 2006; 34(4):347-53. PubMed ID: 16764655
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysbiosis of Ocular Surface Microbiota in Patients With Refractive Allergic Conjunctival Diseases.
    Inada N; Shoji J; Harata G; Miyazawa K; He F; Tomioka A; Hirota A; Tonozuka Y; Yamagami S
    Cornea; 2022 Oct; 41(10):1232-1241. PubMed ID: 34879043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis.
    Avunduk AM; Avunduk MC; Erdöl H; Kapicioglu Z; Akyol N
    Ophthalmologica; 2001; 215(4):290-3. PubMed ID: 11399937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Allergic conjunctivitis].
    Del Río-Navarro BE; Sienra-Monge JJ; Castellanos A; Williams-Gotti MJ
    Bol Med Hosp Infant Mex; 1992 Apr; 49(4):201-4. PubMed ID: 1305389
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosing and managing allergic conjunctivitis in childhood: The allergist's perspective.
    Fauquert JL
    Pediatr Allergy Immunol; 2019 Jun; 30(4):405-414. PubMed ID: 30742722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment.
    Ono SJ; Abelson MB
    J Allergy Clin Immunol; 2005 Jan; 115(1):118-22. PubMed ID: 15637556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostics and new developments in the treatment of ocular allergies.
    Kari O; Saari KM
    Curr Allergy Asthma Rep; 2012 Jun; 12(3):232-9. PubMed ID: 22382607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis.
    el-Asrar AM; Tabbara KF; Geboes K; Missotten L; Desmet V
    Am J Ophthalmol; 1996 Feb; 121(2):156-61. PubMed ID: 8623884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular allergy test and biomarkers on the ocular surface: Clinical test for evaluating the ocular surface condition in allergic conjunctival diseases.
    Shoji J
    Allergol Int; 2020 Oct; 69(4):496-504. PubMed ID: 32563624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.
    Kheirkhah A; Zavareh MK; Farzbod F; Mahbod M; Behrouz MJ
    Eye (Lond); 2011 Jul; 25(7):872-80. PubMed ID: 21475312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.
    Wakamatsu TH; Tanaka M; Satake Y; Dogru M; Fukagawa K; Igarashi A; Fujishima H
    Mol Vis; 2011 Apr; 17():932-8. PubMed ID: 21541276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of Damage-Associated Molecular Patterns (DAMPs/Alarmins) in Severe Ocular Allergic Diseases.
    Fukuda K; Ishida W; Kishimoto T; Nakajima I; Miura Y; Sumi T; Yamashiro K
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.